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Objectives. To investigate the add-on eﬀect of solifenacin for Japanese men with remaining overactive bladder (OAB) symptoms
after tamsulosin monotherapy for lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) in real-
life clinical practice. Methods. Patients aged ≥ 50 having remaining OAB symptoms (≥ 3 of OAB symptom score (OABSS) with ≥2
of urgency score) after at least 4 weeks treatment by 0.2mg of tamsulosin for BPO/LUTS received 2.5 or 5.0mg of solifenacin for
12 weeks. The International Prostate Symptom Score (IPSS), QOL index and OABSS, maximum ﬂow rate (Qmax) and postvoid
residualurinevolume(PVR)weredetermined.Results.Atotalof48patients(meanage72.5years)completedthestudy.Therewere
signiﬁcant improvement in IPSS (15.1 to 11.2) and QOL index (4.2 to 3.0) by add-on of solifenacin. Although the IPSS storage
symptom score was signiﬁcantly improved, there were no changes observed in the IPSS voiding symptom score. The OABSS
showed signiﬁcant improvement (8.0 to 4.8). No changes were observed in Qmax and PVR. Conclusions. Under the supervision
of an experienced urologist, the additional administration of solifenacin to patients with BPO/LUTS treated with tamsulosin, is
eﬀective in controlling remaining OAB symptoms.
1.Introduction
Overactive bladder (OAB) symptoms are commonly
observed in men with lower urinary tract symptoms (LUTS)
suggestive of benign prostatic obstruction (BPO) [1]. Since
α1-blocker monotherapy is eﬃcacious in improving voiding
symptoms and to a certain extent OAB symptoms [2, 3],
it is recommended as the ﬁrst line treatment for men with
BPO+OAB [4]. However, remaining OAB symptoms are
sometimes experienced, and such symptoms continuously
impair quality of life (QOL).
To control OAB symptoms in men with BPO/LUTS,
there are four strategies for medical treatment: adminis-
tration of anticholinergic agent as the ﬁrst line treatment
[5], replace α1-blocker with anticholinergic agent [6], the
combination of α1-blocker and anticholinergic agent as the
ﬁrst line treatment [7–10], and additional administration of
anticholinergic agent [1, 11, 12]. According to the treatment
recommendationsproposedbythe6thInternationalConsul-
tationonNewDevelopmentsinProstateCancerandProstate
Diseases [13], α1-blocker and anticholinergic combination
therapy is recommended as a ﬁrst line treatment for men
with coexisting bladder outlet obstruction (BOO)+OAB
symptoms. However, when we consider the promising
eﬃcacy of α1-blockers on OAB symptoms in men with
BPO and adverse events as well as increased medical cost of2 Advances in Urology
anticholinergic agents, the add-on of anticholinergic agent
following α1-blocker monotherapy seems to be clinically
practical and acceptable.
Although several well-designed trials have indicated the
add-on eﬃcacy and safety of anticholinergic agents such
as tolterodine [1, 11] and solifenacin [12], it remains
unknown whether the evidence derived from the trials, most
of which were performed in western countries, with strict
inclusion and exclusion criteria can be applicable to elderly
Japanesepatientswhohavepastillnessandcomorbiditywith
medication with real-world medication.
Tamsulosin hydrochloride having higher selectivity for
α1A receptor subtype is one of the most frequently used
α1-blockers in Japan since 1993. The approved dosage of
tamsulosin is 0.2mg/day in Japan. Solifenacin succinate
launched in 2006 is the ﬁrst available anticholinergic agent
having higher selectivity for M3 receptor subtype approved
for patients with OAB symptoms in Japan [14]. However,
its eﬃcacy and safety for men with BOO have not been
demonstratedyet.Inthisstudy,weprospectivelyinvestigated
the add-on eﬀect of solifenacin for Japanese men with
remaining OAB symptoms after monotherapy with α1-
blocker, tamsulosin in real-life clinical practice.
2. Patientsand Methods
Since this multi-institutional study was conducted in a real-
life clinical practice setting, no strict inclusion criteria were
applied. Between January 2008 and June 2009, patients
aged 50 or older who reported that they were bothered by
remaining OAB symptoms even after at least 4 weeks of
treatment by 0.2mg of tamsulosin hydrochloride once a day
for LUTS suggestive of BPO were candidates for the study.
Remaining OAB symptoms were deﬁned as 3 or higher of
the sum score of overactive bladder symptom score (OABSS)
with 2 or higher of question 3 (urgency) score [15].
Indication of additional administration of solifenacin
succinate was clinically decided based on experience of each
urologist by concerning comorbidity, maximum ﬂow rate
(Qmax), postvoid residual urine volume (PVR), and so
forth to minimize development of acute urinary retention.
Solifenacin, 2.5 or 5.0mg once a day (the dosage was selected
by the physician based on the patient’s age and comorbidity),
was given for 12 weeks. During the study period, a change
in type and dosage of α1-blocker was not allowed. The
International Prostate Symptom Score (IPSS), QOL index,
OABSS, Qmax, and PVR were determined before and after
treatment. If there were adverse events observed, the severity,
duration, and outcome were recorded.
Statistical comparisons of the mean values between
before and after treatment of solifenacin were done using
parametricpairedt-test.Forcomparisonbetween2.5mgand
5.0mg of solifenacin, unpaired t test was used. P<. 05 was
considered statistically signiﬁcant.
3. Results
3.1. Patient Population. Fifty-seven men were enrolled in
the study. Analysis for safety was done using 52 patients
Table 1:ChangeinIPSSandQOLindexbeforeandaftersolifenacin
treatment (n = 48).
Parameter Before 12 weeks P-value(2)
Incomplete emptying 2.0±1.7(1) 1.3±1.3 P<. 01
Day frequency 2.7±1.4 2.0±1.2 P<. 001
Intermittency 1.6±1.7 1.4±1.3 P = .516
Urgency 2.8 ±1.5 1.5±1.2 P<. 001
Weak stream 2.3±1.7 1.9±1.5 P = .066
Straining 0.9±1.2 0.9±1.2 P = .644
Nocturia 3.0±1.2 2.2±1.2 P<. 001
IPSS storage symptoms 8.5±2.9 5.6±2.6 P<. 001
IPSS voiding symptoms 4.7±3.7 4.2±3.2 P = .253
IPSS total score 15.1±5.9 11.2±5.1 P<. 001
QOL index 4.2±1.2 3.0±1.2 P<. 001
(1)Mean ±SD. (2)Paired t-test.
because 5 men never come back to the hospital after the
ﬁrst administration of solifenacin. Of the 52, 48 patients
completed the study and were provided for the eﬃcacy
analysis. Four patients were withdrawn because of adverse
events.
The age in the eﬃcacy population was 72.5±7.9 years
old (mean±SD). 54.2% of the patients had comorbidity
such as hypertension (n = 19), diabetes mellitus (n =
5), history of cerebral infarction (n = 4), angina pectoris
(n = 2), and others (n = 4) at the start of solifenacin. At
baseline, average IPSS, QOL index, OABSS, Qmax, and PVR
were 15.1, 4.2, 8.0, 10.8ml/sec, and 16.6ml, respectively. No
patients had PVR greater than 100ml. The average dosage
of solifenacin given was 4.3mg/day (31 patients: 5.0mg/day,
17 patients: 2.5mg/day). No patients changed the dosage
of solifenacin during the study period. The patients having
2.5mgwereolder(75.1±5.7years)thanthosehaving5.0mg
of solifenacin (71.2±8.6 years), although no statistical
diﬀerence was observed (P = .068).
3.2. Eﬃcacy Analysis. The IPSS and QOL index were sig-
niﬁcantly improved by the additional administration of
solifenacin (Table 1). Although the storage symptom score
(day frequency, urgency, and nocturia) and postmicturi-
tion symptom (incomplete emptying) were signiﬁcantly
improved, there were no changes observed in voiding symp-
tom score (intermittency, weak stream, straining). OABSS
and each symptom showed signiﬁcant improvement by add-
on of solifenacin (Table 2) .N oc h a n g e sw e r eo b s e r v e di n
Qmax (10.8±6.2 to 13.3±9.9ml/sec., P = .118, n = 36)
and PVR (16.6±23.3 to 15.8±22.7ml, P = .815, n =
45), although one patient showed signiﬁcant increase of
PVR from 62 to 246ml. There were 32 patients with urge
incontinence deﬁned as 1 or greater of score of Q4 (urinary
incontinence) in OABSS at baseline (32 of 48 men, 66.7%).
Urgeincontinencewasdisappearedin18patients(56.3%)by
solifenacin treatment.
There were no diﬀerences in the patterns of changes
in the IPSS storage symptoms (signiﬁcant decrease), the
IPSS voiding symptoms (no change), OABSS (signiﬁcantAdvances in Urology 3
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Figure 1: Changes in parameters before and after 2.5mg and 5.0mg of solifenacin treatment. White and black circles indicated mean value of
2.5mg and 5.0mg of solifenacin, respectively. (a) The IPSS storage symptoms (line) and the IPSS voiding symptoms (dotted lines) 2.5mg:
n = 16, 5.0mg: n = 32, (b) OABSS, 2.5mg: n = 16, 5.0mg: n = 32, and (c) Qmax (line, 2.5mg: n = 12, 5.0mg: n = 24) and PVR (dotted
lines, 2.5mg: n = 15, 5.0mg: n = 30).
Table 2: Change in OABSS before and after solifenacin treatment
(n = 48).
Parameter Before 12 weeks P-value(2)
Daytime frequency 0.9±0.6(1) 0.6±0.5 P<. 05
Nighttime frequency 2.5±0.7 2.0±1.0 P<. 001
Urgency 3.1 ±1.0 1.5±1.3 P<. 001
Urgency incontinence 1.5±1.4 0.7±1.2 P<. 001
OABSS 8.0 ±2.5 4.8±2.6 P<. 001
(1)Mean ±SD. (2)Paired t-test.
decrease),Qmax(nochange),andPVR(nochange)between
2.5mg and 5.0mg of solifenacin (Figure 1). No statistical
diﬀerences were observed in the amount of changes in
the IPSS storage symptoms (−2.3±1.9 versus −3.1±2.8,
P = .282), the IPSS voiding symptoms (−0.3±2.6 versus
−0.5±3.1, P = .757), OABSS (−2.6±2.3 versus −3.4±3.0,
P = .320), Qmax (2.1±6.8 versus 2.2±8.8, P = .977), and
PVR (−1.3±15.9 versus −0.5±24.1, P = .891).
3.3. Safety Analysis. Of the 52 patients of the safety popula-
tion, 9 adverse events were observed in 7 patients (13.5%).
Of the 7, 2 (2 of 17: 11.8%) and 5 (5 of 35: 14.3%) received
2.5mg and 5.0mg of solifenacin, respectively. Constipation
was the most frequent adverse event reported in 3 patients
( 5 . 8 % ) ,t h e nd r ym o u t hi n2( 3 . 9 % ) ,d i ﬃculty of voiding
in 2 (3.9%), increased PVR in 1 (1.9%), and elevated liver
enzymein1(1.9%).DiﬃcultyofvoidingorincreasedPVRin
3 patients disappeared following termination of solifenacin
during the study period. Solifenacin could be continued by
the end of study period in the remaining 4 patients because
adverse events were mild in degree. One patient (1.9%) quit
taking solifenacin because of symptomatic worsening.
4. Discussion
α1-blocker is an eﬃcacious treatment modality to reduce
overactive bladder symptoms in patients with LUTS sugges-
tiveofBPO.AccordingtotheJapan-TamsulosinI-PSSSurvey
[2]conductedasthenation-widepostmarketing surveillance
of tamsulosin in 5,363 patients with BPO/LUTS, 12 weeks of
tamsulosin treatment signiﬁcantly improved the IPSS from
16.7 to 8.6 and the QOL index from 4.5 to 2.5. In the
study, not only the IPSS voiding symptom score but also
the IPSS storage symptom score were signiﬁcantly improved
from 7.1 to 3.4 and 7.2 to 4.1, respectively. Similar result
was obtained when 50mg of naftopidil was given to patients
with BPO/LUTS [3]. However, persisting storage symptoms
not responding to α1-blockers are frequently observed in a
clinical setting [1]. In the subjects evaluated in our study,
despite of administration of tamsulosin, the IPSS and QOL
index were 15.1 and 4.2, respectively. The IPSS voiding
symptoms seemed to be well controlled by tamsulosin
monotherapy although no data before tamsulosin treatment
wereavailable.Ontheotherhand,duetoinclusioncriteriato
deﬁne remaining OAB symptoms, the IPSS storage symptom
score remained high comparable to that before α1-blocker
treatment [2, 3]. Thus, additional treatment is mandatory
for BPO/LUTS patients with persisting OAB symptoms to
further improve their QOL.4 Advances in Urology
Remaining OAB symptoms are mainly caused by detru-
sor overactivity rather than BPO. There are several mecha-
nisms to explain the highly frequent association of bladder
overactivity with BPO/LUTS such as denervation hypersen-
sitivity, modulated detrusor properties, increased release of
urothelial neurotransmitters, and increased aﬀerent stimula-
tion from the urethra [4]. Since anticholinergic agents con-
tribute to improve OAB symptoms through the blockade of
muscarinicreceptorsonthesmoothmuscle,urothelium,and
aﬀerent nerves, they may be eﬀective to control remaining
OAB symptoms after α1-blockers monotherapy.
In the present study, additional administration of solife-
nacin for patients with BPO/LUTS treated with tamsulosin
revealed signiﬁcant improvement of the remaining OAB
symptoms without deterioration of voiding symptoms,
Qmax, and PVR. In addition, neither acute urinary retention
nor severe adverse events were observed during the study
period.
There are several well-designed prospective trials that
investigate the add-on eﬃcacy and safety of anticholinergic
agent after α1-blocker monotherapy. Lee et al. [1]a d d e d
4mg/day of tolterodine for 44 men with urodynamically
proven BOO+OAB who failed 2–4mg/day of doxazosin
monotherapy for 3 months. Thirty-two men (73%) showed
symptomatic improvement deﬁned as a decrease in IPSS
of >3 points by adding of tolterodine. Chapple et al. [11]
conducted a randomized double-blind trial in men with
remaining OAB symptoms (mean urinary frequency ≥8
times per 24 hours including ≥1 micturition-related urgency
episode per 24 hours) with “some moderate” bladder-related
problems on the Patient Perception of Bladder Condition
(PBSC) after α1-blocker monotherapy (alfuzosin, doxazosin,
or tamsulosin) at least for 4 weeks. A total of 652 men were
randomly allocated into placebo+α1-blocker (n = 323) or
tolterodine ER 4mg+α1-blocker (n = 329) for 12 weeks.
Although no signiﬁcant diﬀerence in PBSC improvement as
the primary end point was observed between the 2 groups,
men with tolterodine ER+α1-blocker showed signiﬁcantly
greater improvements in storage symptoms such as urinary
frequency, urgency, the IPSS storage symptom score, and
OAB-q symptom bother scale. There were no clinically
meaningful changes in Qmax and PVR. Kaplan et al. [12]
reported the eﬃcacy and tolerability of solifenacin add-on
to men with residual urgency and frequency (mean urinary
frequency ≥8 times per 24 hours including ≥1u r g e n c y
episode per 24 hours in a bladder diary) after 0.4mg/day of
tamsulosin for 4 or more weeks. A total of 398 men were
randomized to 12 weeks of solifenacin 5mg+tamsulosin
(n = 202) or placebo+tamsulosin (n = 195). Although
there were no signiﬁcant diﬀerences in reductions of urinary
frequency per 24 hours (−1.05 versus −0.67, P = .135)
and the IPSS storage symptom score (−2.80 versus −2.33,
P = .074) between the 2 groups, urgency episode per 24
hours was signiﬁcantly reduced in the group with add-on
of solifenacin (−2.16 versus −1.10, P<. 001). Urinary
retention was reported for 7 patients (3%) and required
catheterization on solifenacin+tamsulosin whereas none
was reported on placebo+tamsulosin. Thus, they concluded
that solifenacin+tamsulosin was well tolerated although
closer supervision may be required for men with severe
BOO.
There are several studies that investigated the add-on
eﬀects of anticholinergic agents after α1-blockers monother-
apy in Japan [16–22]. Although the studies investigated very
small number of patients using various protocols in terms
of type of proceeding α1-blockers (tamsulosin [17, 19],
naftopidil, silodosin [21], combined [16, 20, 22]), required
minimum duration of α1-blockers monotherapy by admin-
istration of anticholinergic agents (2 weeks [19], 4 weeks
[16–18, 21, 22]), type of anticholinergic agents (propiverine
[16], solifenacin [17–19], tolterodine [20], imidafenacin [21,
22]), and duration of add-on (2 weeks [21], 4 weeks [16,
18, 19], 8 weeks [17, 20, 22]), most of studies demonstrated
similar results that the IPSS, QOL index, the IPSS storage
symptoms, and OABSS were improved and the IPSS voiding
symptoms remained unchanged by add-on of anticholiner-
gic agents. No worsening of Qmax and PVR was observed
except in one report [16]. In addition, no studies reported
development of acute urinary retention. It is interesting that
relatively consistent results were achieved even though each
study had limited power to draw conclusion due to small
numbers of patients with diﬀerent type and dosage of αl-
blockers and anticholinergic agents.
Thereislimitedinformationondosageofanticholinergic
agent when the balance between the eﬃcacy and safety is
considered. It is reported that either 2.5mg or 5.0mg of
solifenacin was eﬀective and safe in the previous studies in
[17–19]. In our study, there were no obvious diﬀerences in
eﬃcacy and safety between 2.5mg and 5.0mg of solifenacin,
where dosage was decided based on experience of each
urologist. Although there are no criteria to select appropriate
candidates for the combination in the literature, age, general
condition, comorbidity, degree of BPO estimated by prostate
volume, Qmax, and PVR, and so forth may be considered
when the indication and dosage of solifenacin were decided
in our study. In fact, no patients with 100ml or larger PVR
were enrolled in the study despite of no deﬁnitive criterion
for PVR.
Thus, add-on of anticholinergic agents is promising
also in Japan, although a well-designed large-scale study is
lacking. The prospective randomized study that investigated
the add-on of 10mg or 20mg of propiverine for men who
failed 0.2mg of tamsulosin monotherapy for 8 weeks is now
under preparation for publication [23].
There was limitation in this study. Since we did not eval-
uate the prostate volume just before add-on of solifenacin,
some men might not have benign prostatic enlargement
origin in LUTS. Thus, the eﬃcacy and safety of solifenacin
according to the prostate volume were unknown.
In conclusion, under the supervision of an experienced
urologist, the additional administration of solifenacin to
patients with BPO/LUTS treated with α1-blockers is eﬀective
in controlling remaining OAB symptoms and in improving
QOL. The eﬃcacy and safety of add-on of solifenacin as
well as selection criteria and appropriate dosage should be
investigated in a large-scale randomized study.Advances in Urology 5
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